Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 30, Issue 10, 2011, Pages 1213-1221

  Guzman Fulgencio M ^a   Berenguer, J ^b   Garcia Alvarez M ^a   Micheloud, D ^a,b   Lopez J C ^b   Cosin J ^b   Fernandez De Castro I ^a   Catalan P ^b   Miralles, P ^b   Resino, S ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; FAS ANTIGEN; FAS LIGAND; INTERCELLULAR ADHESION MOLECULE 1; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CARDIOVASCULAR RISK; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TREATMENT DURATION; VIRAL CLEARANCE;

ADULT; ANTIGENS, CD95; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FAS LIGAND PROTEIN; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; RIBAVIRIN; TREATMENT OUTCOME;

EID: 80054774988     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1215-0     Document Type: Article

References (45)

1. A Strasser PJ Jost S Nagata 2009 The many roles of FAS receptor signaling in the immune system Immunity 30 2 180 192 19239902 10.1016/j.immuni.2009.01. 001 1:CAS:528:DC%2BD1MXltFSmsbw%3D
2. L Xerri E Devilard J Hassoun C Mawas F Birg 1997 Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues Mol Pathol 50 2 87 91 9231156 10.1136/mp.50.2.87 1:STN:280:DyaK2sznsVOjtQ%3D%3D
3. TA Ferguson TS Griffith 2006 A vision of cell death: Fas ligand and immune privilege 10 years later Immunol Rev 213 228 238 16972907 10.1111/j.1600-065X.2006.00430.x 1:CAS:528:DC%2BD28XhtF2lsrfP
4. SH Lee MS Shin JY Lee WS Park SY Kim JJ Jang SM Dong EY Na CS Kim SH Kim NJ Yoo 1999 In vivo expression of soluble Fas and FAP-1: possible mechanisms of Fas resistance in human hepatoblastomas J Pathol 188 2 207 212 10398166 10.1002/(SICI)1096-9896(199906)188:2<207::AID-PATH337>3.0.CO;2-8 1:CAS:528:DyaK1MXjvFKjuro%3D
5. N Nonomura K Nishimura Y Ono T Fukui Y Harada N Takaha S Takahara A Okuyama 2000 Soluble Fas in serum from patients with renal cell carcinoma Urology 55 1 151 155 10654915 10.1016/S0090-4295(99)00379-9 1:STN:280: DC%2BD3c7hvFSktA%3D%3D
6. N Kayagaki A Kawasaki T Ebata H Ohmoto S Ikeda S Inoue K Yoshino K Okumura H Yagita 1995 Metalloproteinase-mediated release of human Fas ligand J Exp Med 182 6 1777 1783 7500022 10.1084/jem.182.6.1777 1:CAS:528: DyaK2MXpslymtb0%3D
7. P Schneider N Holler JL Bodmer M Hahne K Frei A Fontana J Tschopp 1998 Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity J Exp Med 187 8 1205 1213 9547332 10.1084/jem.187.8.1205 1:CAS:528: DyaK1cXis1Cru7o%3D
8. N Itoh S Yonehara A Ishii M Yonehara S Mizushima M Sameshima A Hase Y Seto S Nagata 1991 The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis Cell 66 2 233 243 1713127 10.1016/0092- 8674(91)90614-5 1:CAS:528:DyaK38XksVWls7Y%3D
9. T Suda S Nagata 1994 Purification and characterization of the Fas-ligand that induces apoptosis J Exp Med 179 3 873 879 7509364 10.1084/jem.179.3.873 1:CAS:528:DyaK2cXhs1WlsrY%3D
10. S Pol V Soriano 2008 Management of chronic hepatitis C virus infection in HIV-infected patients Clin Infect Dis 47 1 94 101 18513148 10.1086/588669 1:CAS:528:DC%2BD1cXosFejur4%3D
11. B Poonia CD Pauza MS Salvato 2009 Role of the Fas/FasL pathway in HIV or SIV disease Retrovirology 6 91 19832988 10.1186/1742-4690-6-91
12. S Raghuraman P Abraham HD Daniel BS Ramakrishna G Sridharan 2005 Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection J Clin Virol 34 1 63 70 16087126 10.1016/j.jcv.2005.01.009 1:CAS:528:DC%2BD2MXns1WlsL8%3D
13. M Bortolami A Kotsafti R Cardin F Farinati 2008 Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease J Viral Hepat 15 7 515 522 18331250 10.1111/j.1365-2893.2008.00974.x 1:STN:280:DC%2BD1czovV2rsw%3D%3D
14. N Hosaka N Oyaizu S Than S Pahwa 2000 Correlation of loss of CD4 T cells with plasma levels of both soluble form Fas (CD95) Fas ligand (FasL) in HIV-infected infants Clin Immunol 95 1 Pt 1 20 25 10794428 10.1006/clim.2000. 4843 1:CAS:528:DC%2BD3cXjt1Kjt7c%3D
15. A Balasubramanian M Koziel JE Groopman RK Ganju 2005 Molecular mechanism of hepatic injury in coinfection with hepatitis C virus and HIV Clin Infect Dis 41 Suppl 1 S32 S37 16265611 10.1086/429493 1:CAS:528:DC%2BD2MXmtVajsb0%3D
16. DH Dockrell 2003 The multiple roles of Fas ligand in the pathogenesis of infectious diseases Clin Microbiol Infect 9 8 766 779 14616696 10.1046/j.1469-0691.2003.00669.x 1:CAS:528:DC%2BD3sXnvF2mtbw%3D
17. X Volkmann U Fischer MJ Bahr M Ott F Lehner M Macfarlane GM Cohen MP Manns K Schulze-Osthoff H Bantel 2007 Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver Hepatology 46 5 1498 1508 17705261 10.1002/hep.21846 1:CAS:528:DC%2BD2sXhtlOiu7bI
18. MM Melendez MA McNurlan DC Mynarcik S Khan MC Gelato 2008 Endothelial adhesion molecules are associated with inflammation in subjects with HIV disease Clin Infect Dis 46 5 775 780 18225982 10.1086/527563 1:CAS:528: DC%2BD1cXjslWgtrg%3D
19. C Hadigan S Borgonha J Rabe V Young S Grinspoon 2002 Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy Metabolism 51 9 1143 1147 12200758 10.1053/meta.2002.34704 1:CAS:528:DC%2BD38XntVShs78%3D
20. M Duong JM Petit L Piroth M Grappin M Buisson P Chavanet P Hillon H Portier 2001 Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy J Acquir Immune Defic Syndr 27 3 245 250 11464143 10.1097/00042560-200107010-00005 1:STN:280:DC%2BD3MvhtlOrug%3D%3D
21. C Torti A Patroni C Tinelli I Sleiman E Quiros-Roldan M Puoti F Castelli 2002 Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy J Acquir Immune Defic Syndr 29 3 315 317 11873084
22. F Negro AJ Sanyal 2009 Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data Liver Int 29 Suppl 2 26 37 19187070 10.1111/j.1478-3231.2008.01950.x 1:CAS:528:DC%2BD1MXjslaksrw%3D
23. AA Butt W Xiaoqiang M Budoff D Leaf LH Kuller AC Justice 2009 Hepatitis C virus infection and the risk of coronary disease Clin Infect Dis 49 2 225 232 19508169 10.1086/599371
24. DP Kotler 2009 Hepatitis C, human immunodeficiency virus and metabolic syndrome: interactions Liver Int 29 Suppl 2 38 46 19187071 10.1111/j.1478-3231. 2008.01951.x 1:CAS:528:DC%2BD1MXjslaksr0%3D
25. R Bedimo AO Westfall M Mugavero H Drechsler N Khanna M Saag 2010 Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients HIV Med 11 7 462 468 20163481 1:STN:280: DC%2BC3cnnslamtg%3D%3D
26. S Blankenberg HJ Rupprecht C Bickel D Peetz G Hafner L Tiret J Meyer 2001 Circulating cell adhesion molecules and death in patients with coronary artery disease Circulation 104 12 1336 1342 11560847 10.1161/hc3701.095949 1:CAS:528:DC%2BD3MXnslCls7c%3D
27. LM Blanco-Colio JL Martín-Ventura E de Teresa C Farsang A Gaw G Gensini LA Leiter A Langer P Martineau G Hérnandez J Egido 2007 Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST Arterioscler Thromb Vasc Biol 27 1 168 174 17053166 10.1161/01.ATV.0000250616.26308.d7 1:CAS:528:DC%2BD28XhtlSrsLbN
28. JL Martín-Ventura LM Blanco-Colio B Muñoz-García A Gómez-Hernández A Arribas L Ortega J Tuñón J Egido 2004 NF-kappaB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability Stroke 35 2 458 463 14739407 10.1161/01.STR.0000114876.51656.7A
29. YJ Geng LE Henderson EB Levesque M Muszynski P Libby 1997 Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells Arterioscler Thromb Vasc Biol 17 10 2200 2208 9351390 10.1161/01.ATV.17.10.2200 1:CAS:528:DyaK2sXntlOjur8%3D
30. J Berenguer JM Bellón P Miralles E Alvarez M Sánchez-Conde J Cosín JC López F Alvarez P Catalán S Resino 2007 Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data J Viral Hepat 14 12 859 869 18070289 1:STN:280:DC%2BD2sjjsVShug%3D%3D
31. N Hayashi E Mita 1997 Fas system and apoptosis in viral hepatitis J Gastroenterol Hepatol 12 9-10 S223 S226 9407341 10.1111/j.1440-1746.1997. tb00504.x 1:CAS:528:DyaK2sXnvFKqs74%3D
32. TW Lapinski J Jaroszewicz A Wiercinska-Drapalo 2006 Concentrations of soluble Fas and soluble Fas ligand as indicators of programmed cell death among patients coinfected with Human Immunodeficiency Virus and Hepatitis C Virus Viral Immunol 19 3 570 575 16987075 10.1089/vim.2006.19.570 1:CAS:528: DC%2BD28Xpslaksbg%3D
33. G Herbein KA Khan 2008 Is HIV infection a TNF receptor signalling-driven disease? Trends Immunol 29 2 61 67 18178131 10.1016/j.it.2007.10.008 1:CAS:528:DC%2BD1cXhslGitL0%3D
34. A Moanna R Dunham M Paiardini G Silvestri 2005 CD4+ T-cell depletion in HIV infection: killed by friendly fire? Curr HIV/AIDS Rep 2 1 16 23 16091244 10.1007/s11904-996-0004-3
35. L Capa V Soriano J García-Samaniego M Nuñez M Romero A Cascajero F Muñoz J González-Lahoz JM Benito 2007 Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4(+) and CD8(+) T-cell responses to hepatitis C virus J Med Virol 79 5 503 510 17385690 10.1002/jmv.20856 1:CAS:528:DC%2BD2sXkvFykt7s%3D
36. R Cardin G Saccoccio F Masutti S Bellentani F Farinati C Tiribelli 2001 DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an open population study J Hepatol 34 4 587 592 11394660 10.1016/S0168-8278(00)00098-2 1:CAS:528:DC%2BD3MXjvVertbc%3D
37. S Bruno A Crosignani P Maisonneuve S Rossi E Silini MU Mondelli 2007 Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study Hepatology 46 5 1350 1356 17680653 10.1002/hep.21826 1:CAS:528:DC%2BD2sXhtlOiu7vL
38. E Cosson AF Bringuier J Paries R Guillot J Vaysse JR Attali G Feldmann P Valensi 2005 Fas/Fas-Ligand pathway is impaired in patients with type 2 diabetes. Influence of hypertension and insulin resistance Diabetes Metab 31 1 47 54 15803113 10.1016/S1262-3636(07)70166-0 1:CAS:528:DC%2BD2MXivVOku7s%3D
39. C Xu S Lee TM Singh E Sho X Li M Sho H Masuda CK Zarins 2001 Molecular mechanisms of aortic wall remodeling in response to hypertension J Vasc Surg 33 3 570 578 11241129 10.1067/mva.2001.112231 1:STN:280:DC%2BD3M7pvVamsQ%3D%3D
40. K Wolf DA Tsakiris R Weber P Erb M Battegay 2002 Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1 J Infect Dis 185 4 456 462 11865397 10.1086/338572 1:CAS:528:DC%2BD38XhvF2rtrY%3D
41. P Ryan J Berenguer D Michelaud P Miralles JM Bellón E Alvarez P Catalán M Sánchez-Conde S Resino 2009 Insulin resistance is associated with advanced liver fibrosis and high body mass index in HIV/HCV-coinfected patients J Acquir Immune Defic Syndr 50 1 109 110 19092449 10.1097/QAI.0b013e318186ede8
42. N Sattar A McConnachie AG Shaper GJ Blauw BM Buckley AJ de Craen I Ford NG Forouhi DJ Freeman JW Jukema L Lennon PW Macfarlane MB Murphy CJ Packard DJ Stott RG Westendorp PH Whincup J Shepherd SG Wannamethee 2008 Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies Lancet 371 9628 1927 1935 18501419 10.1016/S0140- 6736(08)60602-9
43. K Park M Steffes DH Lee JH Himes DR Jacobs Jr 2009 Association of inflammation with worsening HOMA-insulin resistance Diabetologia 52 11 2337 2344 19680627 10.1007/s00125-009-1486-5 1:CAS:528:DC%2BD1MXht1Cis7nE
44. A Lecube C Hernández J Genescà R Simó 2006 Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study Diabetes Care 29 5 1096 1101 16644643 10.2337/dc05-2509 1:CAS:528:DC%2BD28XkvVKqur4%3D
45. E Marín-Serrano C Rodríguez-Ramos F Díaz L Martín-Herrera JA Girón-González 2006 Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin J Viral Hepat 13 4 230 234 16611188 10.1111/j.1365-2893.2005.00679.x